BCC's goal in conducting this study was to determine the current status of the global therapeutic and diagnostic markets for monoclonal antibodies and their growth potential over a 5 year period from 2007 to 2012. We were particularly interested in the position of the antibody market in the immediate future compared to how it has performed in the recent past as well as how the market compares to that of small molecule pharmaceuticals.
Our key objective was to present a comprehensive analysis of the current monoclonal antibody market and its future direction.
This report contains:
- Descriptions of various types of monoclonal therapeutic and diagnostic antibodies in terms of their history in medicine, their types and technology categories
- The current market status for monoclonal therapeutic and diagnostic antibodies, trends and forecasts for growth over the next 5 years
- Technological issues including the latest trends and a thorough patent analysis
- Analysis of the monoclonal therapeutic and diagnostic antibodies industry on a worldwide basis, both from a market and application perspective
- Discussion of government support in major regions of the world.
BCC presents an analysis of the types of technologies, applications, and therapeutic areas representing financial value in the area of monoclonal antibodies in medicine. Estimated values are based on actual aggregate sales for the years discussed. Information, in general, is compiled through a combination of primary and secondary research, including annual reports and interviews with company officials.
BCC presents an analysis of the types of technologies, applications, and therapeutic areas representing financial value in the area of monoclonal antibodies in medicine. Estimated values are based on actual aggregate sales for the years discussed. Information, in general, is compiled through a combination of primary and secondary research, including annual reports and interviews with company officials.
Kim Johnson is a graduate of Mount Holyoke College with a degree in English Literature. She acquired experience as a health care journalist, including working for John Wiley & Sons for years as a print reporter, before serving as a research analyst in a small market research firm that focused on pharmaceuticals and biotechnology in the Research Triangle Park area of North Carolina. Before joining that firm, Kim published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.
Report Code: BIO016G, Published: January 2008, Analyst: Kim Lawson
